Linear PADRE T helper epitope and carbohydrate B cell epitope conjugates induce specific high titer IgG antibody responses

Journal of Immunology

Volumn 164, Issue 3, 2000, Pages 1625-1633

  Alexander, Jeff ^a   Del Guercio, Marie France ^a   Maewal, Ajesh ^a   Qiao, Lei ^b   Fikes, John ^a   Chesnut, Robert W ^a   Paulson, James ^b   Bundle, David R ^c   DeFrees, Shawn ^b   Sette, Alessandro ^a  

^a Epimmune   (United States)

^b CYTEL CORPORATION   (United States)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIGEN RECOGNITION; ARTICLE; HELPER CELL; IMMUNOSTIMULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SALMONELLA TYPHIMURIUM;

EID: 0034141839     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.164.3.1625     Document Type: Article

References (54)

1. Weissman, I. L., G. A. Gutman, S. H. Friedberg, and L. Jerabek. 1976. Lymphoid tissue architecture. III. Germinal centers, T cells, and thymus-dependent vs thymus-independent antigens. Adv. Exp. Med. Biol. 66:229.
2. Humphrey, J. H., D. M. V. Parrott, and J. East. 1964. Studies on globulin and antibody production in mice thymectomised at birth. Immunology 7:419.
3. Basten, A., and J. G. Howard. 1973. Thymus independence. Contemporary Topics in Immunobiology, A. J. S. Davies, ed. Plenum, New York, p. 265.
4. Winston, D. J., G. H. Winston, G. Schiffman, R. E. Champlin, S. A. Feig, and R. P. Gale. 1983. Pneumococcal vaccination of recipients of bone marrow transplants. Arch. Intern. Med. 143:1735.
5. Williamson, W. A., and B. M. Greenwood. 1978. Impairment of the immune response to vaccination after acute malaria. Lancet 1:1328.
6. Bolan, G., C. V. Broome, R. R. Facklam, B. D. Plikaytis, D. W. Fraser, and W. F. Schlech. 1986. Pneumococcal vaccine efficacy in selected populations in the United States. Ann. Intern. Med. 104:1.
7. Schneerson, R., O. Barrera, A. Sutton, and J. B. Robbins. 1980. Preparation, characterization and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J. Exp. Med. 152:361.
8. Fattom, A., L. Siuru, Y. H. Carbohydrate, A. Burns, A. Hawwari, S. E. Shepherd, R. Couglin, S. Winston, and R. Nasco. 1995. Effect of conjugation methodology, carrier protein, and adjuvants on the immune response to Staphylococcus aureus capsular polysaccharides. Vaccine 13:1288.
9. Peetes, C. A., A. M. Tenbergen-Meekes, D. E. Evenberg, J. T. Poolman, B. J. M. Zegers, and G. T. Rijkers. 1991. A comparative study of the immunogenicity of pneumoacoccal type 4 polysaccharide and oligosaccharide tetanus toxoid conjugates in adult mice. J. Immunol. 146:4308.
10. Robbins, J. B., and R. Schneerson. 1990. Polysaccharide-protein conjugates: a new generation of vaccines. J. Infect. Dis. 161:821.
11. Jennings, H. J., and C. Lugowski. 1981. Immunochemistry of group A, B, and C meningococcal polysaccharide-tetanus toxoid conjugates. J. Immunol. 127:1011.
12. Wessels, M. R., L. C. Paoletti, D. L. Kasper, J. L. DiFabio, F. Micarbohydraten, K. Holme, and J. Jennings. 1990. Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus. J. Clin. Invest. 86:1428.
13. Peeters, C. A., A. M. Tenbergen-Meekes, J. T. Poolman, M. Beurret, B. J. M. Zegers, and G. T. Rijkers. 1991. Effect of carrier priming in immunogenicity of polysaccharide-protein conjugate vaccines. Infect. Immun. 59:3504.
14. Barington, T., A. Gyhrs, K. Kristensen, C., and Heilmann. 1994. Opposite effects of actively and passively acquired immunity to the carrier on response of human infants to Haemophilus influenzae type b conjugate vaccine. Infect. Immun. 62:9.
15. Arnon, R. 1991. Synthetic peptides as the basis for vaccine design. Mol. Immunol. 28:209.
16. Milich, D. R. 1990. Synthetic peptides: prospects for vaccine development. Semin. Immunol. 2:307.
17. Berzofsky, J. A. 1991. Progress toward an artificial vaccine for HIV: identification of helper and cytotoxic T-cell epitopes and methods of immunization. Biotechnol. Ther. 2:123.
18. Chesnut, R. W., A. Sette, E. Celis, P. Wentworth, R. T. Kubo, J. Alexander, G. Ishioka, A. Vitiello, and H. M. Grey. 1995. Design and testing of peptide-based cytotoxic T-cell-mediated immunotherapeutics to treat infectious diseases and cancer. In Vaccine Design: The Subunit and Adjuvant Approach. M. F. Powell and M. J. Newman, eds. Plenum Press, New York, p. 847.
19. Lanzavecchia, A. 1993. Identifying strategies for immune intervention. Science 260:937.
20. Alexander, J., J. Sidney, S. Southwood, J. Ruppert, C. Oseroff, A. Maewal, K. Snoke, H. M. Serra, R. T. Kubo, A. Sette, and H. M. Grey. 1994. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1:751.
21. Alexander, J., J. Fikes, S. Hoffman, E. Franke, J. Sacci, E. Appella, F. V. Chisari, L. G. Guidotti, R. W. Chesnut, B. Livingston, and A. Sette. 1998. The optimization of helper T lymphocyte (HTL) function in vaccine development. Immunol. Res. 18:79.
22. Panina-Bordignon, P., A. Tan, A. Termiftelen, S. Demotz, G. Corradin, and A. Lanzavecchia. 1989. Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur. J. Immunol. 19:2237.
23. del Guercio, M.-F., J. Alexander, R. T. Kubo, T. Arrhenius, A. Maewal, E. Appella, S. L. Hoffman, T. Jones, D. Valmori, K. Sakaguchi, H. M. Grey, and A. Sette. 1997. Potent immunogenic short linear peptide constructs composed of B cell epitopes and Pan DR T helper epitopes (PADRE) for antibody responses in vivo. Vaccine 15:441.
24. Franke, E. D., S. L. Hoffman, J. Sacci Jr., R. Wang, Y. Charoenvit, E. Appella, R. W. Chesnut, J. Alexander, M.-F. del Guercio, and A. Sette. 1999. Pan DR binding sequence provides T-cell help for induction of protective antibodies against Plasmodium yoelii sporozoites. Vaccine 17:1201.
25. Pinto, B. M., and D. R. Bundle. 1983. Preparation of glycoconjugates for use as artificial antigens: A simplified procedure. Carbohydr. Res. 124:313.
26. Bundle, D. R., E. Eichler, M. A. J. Gidney, M. Meldal, A. Ragauskas, B. W. Sigurskjold, B. Sinnott, D. C. Watson, M. Yaguchi, and N. M. Young. 1994. Molecular recognition of a Salmonella trisaccharide epitope by monoclonal antibody SE155-4. Biochemistry 33:5172.
27. Kensil, C. R., J. Y. Wu, and S. Soltysik. 1995. Structural and immunological characterization of the vaccine adjuvant QS-21. In Vaccine Design: The Subunit and Adjuvant Approach. M. R. Powell and M. J. Newman, eds., Plenum Press, New York, 1995.
28. Rietschel, E. T., L. Brade, B. Under, and U. Azhringer. 1992. Biochemistry of lipopolysaccharides. In Bacterial Endotoxic Lipopolysaccharides. D. C. Morrison and J. L. Ryan, eds. CRC Press, Inc, Boca Raton, FL. pp. 3-41.
29. Norberg, T., S. B. Svenson, K. Bock, and M. Meldal. 1985. Immunochemistry of Salmonella O-antigens: studies of Salmonella BO antigen epitopes by enzyne-linked immunosorbent inhibition assays. FEMS Microbiol. Lett. 28:171.
30. Colwell, D. E., S. M. Michalek, D. E. Briles, E. Jirillo, and J. R. McGree. 1984. Monoclonal antibodies to Salmonella lipopolysaccharide: anti-O-polysaccharide antibodies protect C3H mice against challenge with virulent Salmonella typhimurium. J. Immunol. 133:950.
31. Svenson, S. B., and A. A. Lindberg. 1981. Artificial Salmonella vaccines: Salmonella typhimurium O-antigen-specific oligosaccharide-protein conjugates elicit protective antibodies in rabbits and mice. Infect. Immun. 32:490.
32. Slauch, J. M., M. J. Mahan, P. Michetti, M. R. Meutra, and J. J. Mekalonos. 1995. Acetylation (O-Factor 5) affects the structural and immunologicai properties of Salmonella typhimurium lipopolysaccharide O antigen. Infect. Immun. 63:437.
33. Schutze, M.-P., C. Leclerc, M. Jolivet, F. Audibert, and L. Chedid. 1985. Carrier-induced epitopic suppression, a major issue for future synthetic vaccines. J. Immunol. 135:2319.
34. Shinnick, T. M., J. G. Sutcliffe, N. Green, and R. A. Lerner. 1983. Synthetic peptide immunogens as vaccines. Annu. Rev. Microbiol. 37:425.
35. Francis, M. F., C. M. Fry, D. J. Rowlands, J. L. Bittle, R. A. Houghten, R. A. Lerner, and F. Brown. 1987. Immune response to uncoupled peptides of foot-and-mouth disease virus. Immunology. 61:1.
36. Bixler, G. S. Jr., R. Eby, K. M. Dermody, R. M. Woods, R. C. Seid, and S. Pillai. 1989. Synthetic peptide representing a T-cell epitope of CRM197 substitutes as carrier molecule in a Haemophilus infiuenzae type B (Hib) conjugate vaccine. Adv. Exp. Med. Biol. 251:175.
37. Fernández, I. M., A. Snijders, B. J. Benaissa-Trouw, M. Harmsen, H. Snippe, and C. A. Kraaijeveld. 1993. Influence of epitope polarity and adjuvants on the immunogenicity and efficacy of a synthetic peptide vaccine against Semliki Forest virus. J. Virol. 67:5843.
38. Fernández, I. M., M. Harmsen, B. J. Benaissa-Trouw, I. Stuij, W. Puyk, R. H. Meloen, H. Snippe, and C. A. Kraaijeveld. 1998. Epitope polarity and adjuvants influence the fine specificity of the humoral response against Semliki Forest virus specific peptide vaccines. Vaccine 16:1531.
39. Obeid, O. E., C. D. Partidos, C. R. Howard, and M. W. Steward. 1995. Protection against Morbillivirus-induced encephalitis by immunization with a rationally designed synthetic peptide vaccine containing B-and T-cell epitopes from the fusion protein of measles virus, J. Virol. 69:1420.
40. Su, H., and H. D. Caldwell. 1992. Immunogenicity of a chimeric peptide corresponding to T helper and B cell epitopes of the Chlamydia tracarbohydratematis major outer membrane protein. J. Exp. Med. 175:227.
41. Lett, E., S. Gangloff, M. Zimmermann, D. Wachsmann, and J.-P. Klein. 1994. Immunogenicity of polysaccharides conjugated to peptides containing T-and B-cell epitopes. Infect. Immun. 62:785.
42. Levely, M., M. A. Mitchell, and J. A. Nicarbohydratelas. 1990. Synthetic immunogens constructed from T-cell and B-cell stimulating peptides (T:B chimeras): preferential stimulation of unique T-and B-cell specificities is influenced by immunogen configuration. Cell. Immunol. 125:65.
43. van de Wijgert, J. H., A. F. Verheul, H. Snippe, I. J. Check, and R. L. Hunter. 1991. Immunogenicity of Streptococcus pneumoniae type 14 capsular polysaccharide: influence of carriers and adjuvants on isotype distribution. Infect. Immun. 59:2750.
44. ten Hagen, T. L., A. J. Sulzer, M. R. Kidd, A. A. Lal, and R. L. Hunter. 1993. Role of adjuvants in the modulation of antibody isotype, specificity, and induction of protection by whole blood-stage Plasmodium yoelii vaccines. J. Immunol. 151:7077.
45. Fattom, A., R. Schneerson, W. W. Karakawa, D. Fitzgerald, I. Pastan, X Li, J. Shiloach, D. A. Bryla, and J. B. Robbins. 1993. Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus types 5 and 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A. Infect. Immun. 61:1023.
46. Briles, D. E., J. L. Claflin, K. Schroer, and C. Forman. Mouse IgG3 antibodies are highly protective against infection with Streptococcus pneumoniae. Nature 294: 88.
47. Coutelier, J. P., J. T. M. Van Der Logt, F. W. A. Heessen, A. Vink, and J. Van Snick, J. 1988. Virally induced modulation of murine IgG antibody subclasses. J. Exp. Med 168:2373.
48. Spiegelberg, H. L. 1974. Biologic activities of immunoglobulins of different classes and subclasses. Adv. Immunol. 19:259.
49. Takehara, H., A. A. Perini, M. H. da Silva, and I. Mota. 1981. Trypanosoma cruzi role of different antibody classes in protection against infection in the mouse. Exp. Parasitol. 52:137.
50. Ak, M., J. H. Bowler, S. L. Hoffman, M. Sedegah, A. Lees, M. Carter, R. L. Beaudoin, and Y. Charoenvit. 1993. Monoclonal antibodies of three different immunoglobulin G isotypes produced by immunization with a synthetic peptide or native protein protect mice against challenge with Plasmodium yoelii sporozoites. Infect, Immun. 61:2493.
51. Steller, M. A., K. J. Gurski, M. Murakami, R. W. Daniel, K. V. Shah, E. Celis, A. Sette, A., E. L. Trimble, R. C. Park, and F. M. Marincola. 1998. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus Type 16 E7. Clin. Cancer Res. 4:2103.
52. Lüderitz, O., O. Westphal, A. M. Staub, and H. Nikaido. 1971. Isolation and chemical and immunological characterization of bacterial lipopolysaccharides. In Microbial Toxins, Vol. 4. G. Weinbaum, S. Kadis, and S. J. Ajl, eds. Academic Press, New York, p. 145.
53. Lindberg, A. A. 1999. Glycoprotein conjugate vaccines. Vaccine 17:28.
54. Livingston, P. O., and G. Ragupathi. 1997. Carbohydrate vaccines that induce antibodies against cancer. 2. Previous experience and future plans. Cancer Immunol. Immunother. 45:10.